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Objectives: Mycobacterium tuberculosis can exist in different states in vitro, which can be denoted as fast multi-
plying, slowmultiplying and non-multiplying. Characterizing the natural growth of M. tuberculosis could provide a
framework for accurate characterization of drug effects on the different bacterial states.
Methods: The natural growth data of M. tuberculosis H37Rv used in this study consisted of viability defined as cfu
versus time based on data from an in vitro hypoxia system. External validation of the natural growth model was
conducted using data representing the rate of incorporation of radiolabelled methionine into proteins by the
bacteria. Rifampicin time–kill curves from log-phase (0.25–16 mg/L) and stationary-phase (0.5–64 mg/L) cul-
tures were used to assess themodel’s ability to describe drug effects by evaluating different linear and non-linear
exposure–response relationships.
Results: The final pharmacometric model consisted of a three-compartment differential equation system repre-
senting fast-, slow- and non-multiplying bacteria. Model predictions correlated well with the external data
(R2¼0.98). The rifampicin effects on log-phase and stationary-phase cultures were separately and simultan-
eously described by including the drug effect on the different bacterial states. The predicted reduction in log10 cfu
after 14 days and at 0.5 mg/L was 2.2 and 0.8 in the log-phase and stationary-phase systems, respectively.
Conclusions: Themodel provides predictions of the change in bacterial numbers for the different bacterial states
with and without drug effect and could thus be used as a framework for studying anti-tubercular drug effects
in vitro.
Introduction
Tuberculosis, caused by Mycobacterium tuberculosis, is ranked as
the second leading cause of death worldwide due to an infectious
disease.1 One of the underlying problems with efforts to enhance
control of the disease is the persistence of bacteria that cannot be
eradicated by antimicrobial agents or the immune system.
Therefore, new drugs and optimization of the current standard
treatment with the aim of shortening the current treatment dur-
ation are highly important. New tools and strategies are needed to
establish effective predictive model systems to smooth the tran-
sition of laboratory-based data to clinical studies. Since the devel-
opment of new drugs requires large investments, any tool or
strategy that could decrease the risk of failure during late-phase
drug development is naturally interesting. Pharmacometrics has
been promoted as a methodology to rationalize and inform
drug development through the application of mathematical and
statistical methods for the characterization and prediction
of pharmacokinetics and pharmacodynamics. In contrast to
the use of summary endpoints to describe pharmacokinetic–
pharmacodynamic relationships of antibiotics, pharmacometric
models provide integration of the time course of the relationships
between exposure, effect and the underlying disease-specific
mechanisms. Thereby, they provide valuable information for
evaluation of the rational use of existing drug regimens and in
the development of new drugs.
Pharmacometric models have been successfully applied to in
vitro data, e.g. describing antibacterial effects on Streptococcus
pyogenes2–4 and Pseudomonas aeruginosa.5–8 In vitro studies,
offering greater flexibility with regard to study design and being
less expensive to perform, are an attractive complement to
in vivo studies. In order to provide an accurate characterization
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of the in vitro antibacterial effect on M. tuberculosis, characteriza-
tion of in vitro natural growth without drug exposure is needed.
In a tuberculosis infection, multiplying bacteria (defined as
bacteria exhibiting genomic growth and the ability to segregate
into a new self-propagating unit9) and non-multiplying bacteria
can exist side by side.9 Although antibiotics are able to kill multiply-
ing bacteria, most are very ineffective at killing non-multiplying
bacteria.10 Targeting bothmultiplying and non-multiplying popula-
tions is regarded as an essential way of shortening treatment dur-
ation and slowing emergence of drug resistance.11 Quantification
of drug effects on non-multiplying bacteria is hence essential
when targeting a translational modelling framework.
Characterization of antibacterial activity has historically been
performed using bacterial cultures displaying exponential growth,
i.e. cultures that are in log phase. However, regulatory guidelines
have suggested that targeting bacteria from stationary-phase
cultures, or cultures displaying no net growth or death, is import-
ant in the development of newagents as data from these cultures
may indicate sterilizing activity against M. tuberculosis in vivo.12
From the use of hypoxia-driven in vitro systems, stationary-phase
M. tuberculosis has been suggested to be able to exist in what
have been referred to as dormant or non-replicating forms.13,14
Evidence has since shown that M. tuberculosis can exist, both in
vitro and in vivo, in transient bacterial states in which the organ-
isms, while being able to multiply in liquid media, are not able to
form colonies on solidmedia.15–19This has also been shown to be
the case in sputum.20,21 The existence of such a bacterial state is
in line with what has been shown when utilizing a modelling
approach to describe the relationship between cfu and
Mycobacterial Growth Indicator Tube (MGIT) time to positivity
using matched liquid culture and colony count data.22
The dormant bacteria are one part of a simplified classification
comprising three bacterial states—fast-multiplying, slow-multiplying
and non-multiplying—that have been suggested to describe the
cycle of M. tuberculosis growth.11 This simplification represents a
continuum of growth states ranging from fast- to non-multiplying
that most likely exists in humans. Within this context it is import-
ant to address the fact that measurement of cfu counts only
enables quantification of bacilli that can multiply on solid media.
We therefore aimed to develop a population pharmacometric
template model that would allow the study of anti-tubercular
drug effects on the different bacterial states of M. tuberculosis.
External validation of the model predictions using data on the
rate of incorporation of radiolabelled amino acid into proteins by
the bacteria was performed. Themodel’s ability to act as a frame-
work for studying anti-tubercular drug effects was exemplified
and evaluated by characterizing the effect of rifampicin on both
log-phase and stationary-phase bacterial cultures.
Materials and methods
In vitro assays and bacteria
Three types of in vitro assays were used in the viability assessed by cfu: a
natural growth assay without drug effect; a time–kill assay utilizing
log-phase bacterial cultures exposed to rifampicin; and a time–kill assay
utilizing stationary-phase bacterial cultures exposed to rifampicin. An add-
itional in vitro assay assessing the incorporation of [35S]methionine into
M. tuberculosis cells was included as an external validation of the pharma-
cometricmodel.M. tuberculosis strain H37Rvwas used in all in vitro assays.
Natural growth assay
M. tuberculosis strain H37Rv was grown in 7H9 medium supplemented
with 10% albumin dextrose complex (ADC, Becton, Dickinson, UK) and
containing 0.05% Tween 80 at 378C without disturbance for up to
200 days; 12 replicates were included. At different timepoints, the clumps
of bacilli in each of a set of 10 mLcultureswere broken up by vortexingwith
2 mm diameter glass beads for 5 min, followed by sonication in a water
bath sonicator (Branson Ultrasonic, USA) for 5 min to obtain an evenly dis-
persed suspension of bacilli. Viability was estimated by plating a series of
10-fold dilutions of the cultures on 7H11 agarmedium supplementedwith
oleic albumin dextrose complex (OADC, Becton, Dickinson, UK) and defined
as cfu/mL (Figure 1).
Time–kill assays
Log-phase M. tuberculosis H37Rv (grown to 4 days) was incubated with
0, 0.25, 0.5, 1, 2, 4, 8 and 16 mg/L rifampicin at 378C with no replicates.
Stationary-phase cultures (grown to 100 days) were incubated with
0, 0.5, 1, 2, 4, 8, 16, 32 and 64 mg/L rifampicin at 378Cwith two replicates.
Viability of the cultures was determined by cfu counting at days 0, 2, 5, 10,
15, 20 and 30 after drug exposure for the log-phase cultures and at days 0,
3, 6, 10 and 14 after drug exposure for the stationary-phase cultures
(Figure 1).
Pharmacometric model building
To enable a semi-mechanistic description of the in vitro antibacterial effect
on the different states of M. tuberculosis H37Rv, characterization of the
in vitro natural growth of the bacteria without drug effect as quantified
by cfu counting was initially performed. The rifampicin concentration–
effect relationship for the log- and stationary-phase cultures was then
investigated using different linear and non-linear functions.
The natural growth of M. tuberculosis H37Rv was characterized using a
model with three bacterial states (Figure 2). The basis of the model devel-
opment was a system with three differential equations (equations 1–3),
representing fast-, slow- and non-multiplying bacteria, for which different
growth functions and transfer rates were evaluated.
dF
dt
= kG · F + kSF · S + kNF · N − kFS · F − kFN · F (1)
dS
dt
= kFS · F + kNS · N − kSF · S − kSN · S (2)
dN
dt
= kFN · F + kSN · S − kNS · N − kNF · N (3)
A reduced form of the model without the non-multiplying state (equation
3) was also evaluated. As the cfu count reflects only the bacteria that are
able to multiply on solid media, only the numbers in the fast- and
slow-multiplying states, as a sum, were part of the model prediction of
the data. Further, as the cfu count is a summary measure of total viable
bacteria, the inoculum is the sum of the initial bacterial numbers in the
fast-multiplying (F0) and the slow-multiplying (S0) states. A model with
estimation of both F0 and S0 was compared with models with either F0
or S0 fixed to 0, representing a situation where all bacteria would be in
the fast-multiplying or slow-multiplying state at the time of inoculum.
The growth rates of the fast-multiplying and slow-multiplying bacteria
were evaluated, as exemplified for the fast-multiplying bacterial state,
using exponential (equation 4), Gompertz (equation 5) and logistic
(equation 6) growth functions
dF
dt
= kG · F (4)
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dF
dt
= kG · log BmaxF + S + N
( )
· F (5)
dF
dt
= kG · [Bmax − (F + S + N)] · F (6)
in which kG is the growth rate and Bmax is the system-specific carrying
capacity. F, S and N are the bacterial numbers predicted by the model in
the fast-, slow- and non-multiplying states, respectively. As discussed
above, the cfu count reflects only the bacteria that are able to multiply
on solid media (fast and slow). The non-multiplying state was, however,
allowed to influence the predictions as described in equations (5 and 6).
Equations (5 and 6) were also evaluated without including N. In the sim-
plest model structure, still involving the three bacterial states, bacterial
movement between the different states can be described via first-order
linear rate constants relating to the transfer from one state to another.
The transfer rate of fast-multiplying to slow-multiplying bacteria (kFS)
was evaluated as a constant transfer rate and as a transfer rate that incor-
porated stimulation of transfer by the total number of bacteria in the fast-,
slow- and non-multiplying states (equation 7). Further, time dependency
in the fast-to-slow transfer was evaluated using a linear (equation 8)
and an Emax (equation 9) and an exponential (equation 10) function. For
equations 8–10 kFS will be 0 at the start of the experiment (time¼0).
kFS = kFSstim ·
F + S + N
Bmax
(7)
kFS = kFSlin · t (8)
kFS = kFSsig ·
tmax · t
t50 + t (9)
kFS = 1− e−kFSexp ·t (10)
Here, t is time, tmax is the maximum time and t50 is the time when the
transfer rate has reached 50% of tmax. Initial runs revealed that the rate
of transfer from N to F (kNF) was close to zero and was therefore assumed
to be negligible and thus fixed to 0 in further model development.
The effects of rifampicin on cultures in log phase and stationary phase
were evaluated separately using rifampicin data, natural growth data and
fixed parameter estimates from the natural growth model. The para-
meters kG, Bmax, F0 and S0 were evaluated for significant differences
between the natural growth and the log and stationary natural growth
control experiments.
The effects of rifampicin were evaluated, where applicable, as inhib-
ition of growth and kill rates on each of the three bacterial states using
linear functions (equation 11), ordinary Emax functions (equation 12) and
sigmoidal Emax functions (equation 13):
E = k · CRIF (11)
E = Emax · CRIF
EC50 + CRIF (12)
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Figure 1. Mean observed log10 cfu versus time. (a) Combination plot of all the data from the three in vitro systems: the 200 day natural growth system;
the log-phase system with and without rifampicin (RIF); and the stationary-phase system with and without RIF. (b) The log-phase system with and
without rifampicin, pre-grown for 4 days and studied for 30 days. (c) The stationary-phase system with and without rifampicin, pre-grown for
100 days and studied for 14 days.
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g
RIF
EC50
g + C gRIF
(13)
where CRIF is rifampicin concentration in the system.
Inhibition of growth by the drug effect (E) was implemented in the dif-
ferential equation system as a fractional inhibition, as exemplified for the
fast-multiplying bacterial state (equation 14),23 whereas the drug effect,
as a kill rate, of the fast-, slow- and non-multiplying states was implemen-
ted as an additive bacterial killing-rate constant imposed by the drug as
exemplified for the slow-multiplying bacterial state (equation 15):24
dF
dt
= kG · (1− E) · F + kSF · S + kNF · N − kFS · F − kFN · F (14)
dS
dt
= kFS · F + kNS · N − kSF · S − kSN · S − E · S (15)
Evaluation of drug effect was conducted by evaluating all possible combi-
nations of effects on the three different bacterial states, where applicable,
as either inhibition of growth or as a kill rate, as well as for the different
exposure–response functions described in equations (11–13). The best
model from this step, judged by criteria outlined below, was evaluated
in a last step by reducing each of the different exposure–response func-
tions to their simpler form in order to confirm the appropriateness of the
final model.
In addition to separately describing the effect of rifampicin on the log-
phase and stationary-phase cultures, an evaluation of the effect of rifam-
picin using data combined from both the log phase and the stationary
phase was performed.
External validation
External validation of the model describing the in vitro natural growth
without drug effect was performed using a dataset consisting of the
rate of incorporation of radiolabelled methionine ([35S]methionine) into
proteins by the bacteria. For incorporation of radioactive methionine
into proteins of M. tuberculosis, 3 mL of 4, 10, 20, 30, 40 and 50 day cul-
tures with 1–2×108 cfu/mL of bacilli were incubated with 30 mCi of
[35S]methionine at 378C for 1 h. Also, 30 mCi of [35S]methionine was
added to heat-killed cultures. Radioactive labelling was terminated after
a chase with 10 mM L-methionine. The bacterial cells were harvested by
centrifugation at 12000 g for 15 min and washed three times with PBS
containing 1 mM L-methionine. Bacterial cells were lysed by vortexing for
5 min with an equal amount of glass beads (75–150 mm, Sigma) in dis-
tilled water. The incorporation of [35S]methionine into total proteins was
determined by scintillation counting of radioactivity and calculated as
cpm of trichloroacetic acid-precipitated proteins.
This was correlated to, as a percentage, the mean of the natural
growth model predicted typical fast-multiplying bacterial number out of
the predicted typical fast- plus slow-multiplying bacterial number, i.e.
100×(F/F+S).
Data analysis and software
All data analysis was performed in the software NONMEM (version 7.3;
Icon Development Solutions, http://www.iconplc.com/technology/
products/nonmem) using the first-order conditional estimation method
with interaction (FOCE INTER).25 R (version 3.2; R Foundation for
Statistical Computing, http://www.R-project.org) was used for data man-
agement and Xpose (version 4.5.0; Department of Pharmaceutical
Biosciences, Uppsala University, http://xpose.sourceforge.net) was used
for graphical assessment of results.26 PsN (version 4.4.5; Department of
Pharmaceutical Biosciences, Uppsala University, http://psn.sourceforge.
net) was used for running models,26 generating visual predictive checks
(VPCs)26 and prediction-corrected visual predictive checks (pcVPCs).27
Numerical model comparison and a run record were utilized and main-
tained with the software Pirana (version 2.9.2; Pirana Software &
Consulting, http://www.pirana-software.com).26 Model evaluation was
done by evaluation of goodness-of-fit plots, precision in parameters,
objective function values (OFVs), scientific plausibility, VPCs and pcVPCs.
The OFV given by NONMEM, which approximates 22 log(likelihood) of
the data given the model, was utilized in likelihood ratio testing (LRT) to
compare nested models. The difference in OFV (DOFV) is approximately
x2 distributed and dependent on the significance level and degrees of free-
dom. For this analysis a significance level of 0.05 was used, which hence
corresponds to a critical DOFV of 3.84 for 1 degree of freedom.
Data below the limit of quantification (LOQ, 25%), was handled using
the M3method,28 with LOQ set to 10 cfu. The LOQwas defined as the low-
est number of bacteria that need to be present in the growth tube to be
able to detect 1 cfu, taking into account the dilution of the plated sample.
Inclusion of variability was evaluated on the parameters F0, S0 and kG
using a log normal variability distribution model.
Results
A schematic representation of the final pharmacometric model
describing the natural growth and the concentration–effect rela-
tionship of rifampicin from the simultaneous fit of the log- and
stationary-phase data is shown in Figure 2 and parameter esti-
mates are given in Table 1.
Natural growth model
The final multistate tuberculosis pharmacometric model
describes the in vitro growth of M. tuberculosis utilizing a fast-, a
slow- and a non-multiplying state. Estimation of the initial bacter-
ial numbers in the fast-multiplying (F0) and the slow-multiplying
(S0) bacterial states resulted in a significant decrease in OFVwhen
compared with fixing either F0 or S0 to 0. Inclusion of variability in
kSF
kFS = kFSLin∑ t
kSN
kNSkFN
SF
N
CRIF
kG 
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log         
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Bmax
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FDEmax ∑ CRIF
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Figure 2. Schematic illustration of the multistate tuberculosis
pharmacometric model with inclusion of rifampicin pharmacokinetics
(drug model). CRIF, rifampicin (RIF) concentration; F, fast-multiplying
state; S, slow-multiplying state; N, non-multiplying state; kG, growth rate
of the fast-multiplying state bacteria; kFS, time-dependent linear rate
parameter describing transfer from fast- to slow-multiplying state; kSF,
first-order transfer rate between slow- and fast-multiplying states; kFN,
first-order transfer rate between fast- and non-multiplying states; kSN,
first-order transfer rate between slow- and non-multiplying states; kNS,
first-order transfer rate between non-multiplying and slow-multiplying
states; FGk, linear drug-induced inhibition of fast-multiplying state
growth; FDEmax , maximum achievable drug-induced fast-multiplying
state kill rate; FDEC50 , concentration at 50% of FDEmax ; SDEmax , maximum
achievable drug-induced slow-multiplying state kill rate; SDEC50 ,
concentration at 50% of SDEmax ; NDk, non-multiplying state kill rate.
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F0 (vF) resulted in a better fit and a significant drop in OFV
(DOFV¼267.5). Growth of the fast-multiplying bacteria, kG, was
best described by a Gompertz function (OFV¼241.5) compared
with the exponential (OFV¼ 325) and the logistic growth function
(OFV¼10.7). Addition of any of the growth functions to the slow-
multiplying state did not result in any significant improvement in
the OFV. The rate of transfer between the fast- and the slow-
multiplying states, kFS, was best described with a time-dependent
linear function (equation 8), which described the data better than
any of the other functions evaluated.
In Figure 3, in the panel entitled natural growth, the predicted
bacterial numbers in the different states over time are shown as a
mean of the 12 replicates. Figure 4 shows a VPC of the final multi-
state tuberculosis pharmacometric model without drug effect
(natural growth).
External validation
The external validation of the final model describing the natural
growth showed a strong correlation (R2¼0.98, Figure 5) between
the rate of incorporation of radiolabelled methionine into pro-
teins by the bacteria and, as a percentage, the mean of the nat-
ural growth model predicted typical fast-multiplying bacterial
number out of the predicted typical fast- plus slow-multiplying
bacterial number, i.e. 100×(F /F+S).
Rifampicin exposure–response models
The rifampicin effect on the bacterial system was linked to the
bacterial system description, the multistate tuberculosis pharma-
cometric model, by including a rifampicin pharmacokinetic
model. The rifampicin pharmacokinetic model consisted of one
compartment accounting for rifampicin in vitro pharmacokinetics
(Figure 2). The in vitro system was a static system where the
exposure remained constant over time. As such, no elimination
from the drug compartment in the model was included. Drugs
can further bind to laboratory material,29 i.e. adherence, resulting
in less available effective drug in the in vitro system. However, no
information about adherence of rifampicin in these systems
was known.
The evaluation of differences between the natural growth con-
trol data from the log-phase cultures and the natural growth data,
due to experimental specific differences, resulted in the inclusion
in the final model of separate and significant (decrease in OFV of
99 points) kG and F0 values for the log-phase natural growth con-
trol data (kGLog and F0Log ) (Table 1). Evaluation in the same manner
using the stationary-phase and natural growth data resulted in
the inclusion in the final model of a separate and significant
(decrease in OFV of 401 points) Bmax for the stationary natural
growth control data (BmaxStationary ) (Table 1). Addition of these para-
meters thus resulted in decreased OFV and allowed a better pre-
diction of the natural growth control data (Figure S1, available as
Supplementary data at JAC Online).
The effect of rifampicin on the different bacterial states was
evaluated separately for the log-phase and stationary-phase cul-
tures, where applicable, as either an inhibition of growth or a kill
rate. A simultaneous evaluation using the log-phase and the
stationary-phase datawas also performed and the final simultan-
eous fit model included inhibition of fast-multiplying bacterial
growth, kill rate of the fast-multiplying bacteria, kill rate of the
slow-multiplying bacilli and kill rate of the non-multiplying bacilli.
The final effect parameterization differed from themodel describ-
ing only the log-phase culture data, which did not support inclu-
sion of a kill rate in the non-multiplying state. The predicted
reduction in log10 cfu after 14 days and at 0.5 mg/L was 2.2 and
0.8 in the log-phase and stationary-phase system, respectively. A
schematic illustration of where the drug effect was implemented
in the multistate tuberculosis pharmacometric model is shown in
Figure 2 and parameter estimates are given in Table 1. The final
differential equation system of the multistate tuberculosis
Table 1. Parameter estimates of the final multistate tuberculosis
pharmacometric model applied to cfu data from rifampicin log- and
stationary-phase M. tuberculosis H37Rv cultures
Parameter Estimate RSE (%)
kFN
a (days21) 0.897×1026 1.2
kSN
a (days21) 0.186 4.3
kSF
a (days21) 0.0145 4.9
kNS
a (days21) 0.123×1022 2.7
kFSLin
a,b (days22) 0.166×1022 1.6
S0
a (mL21) 9770 2.4
kG
a,c (days21) 0.206 1
kGLog
a (days21) 0.102 12.5
F0
a (mL21) 4.1 2.9
F0Log
a (mL21) 674×103 39.2
Bmax
a (mL21) 242×106 4.5
BmaxStationary
a (mL21) 1410×106 0.8
FGk (L.mg
21) 0.017 11.1
FDEmax (days
21) 2.15 4.5
FDEC50 (mg.L
21) 0.52 9.8
SDEmax (days
21) 1.56 4.7
SDEC50 (mg.L
21) 13.4 10.4
NDk (L.mg
21.days21) 0.24 12.6
vF
a (%) 473.3 5.9
Proportional residual error (%) 63.8 7.8
kFN, first-order transfer rate between fast- and non-multiplying state; kSN,
first-order transfer rate between slow- and non-multiplying state; kSF
first-order transfer rate between slow- and fast-multiplying state; kNS,
first-order transfer rate between non- and slow-multiplying state, S0
initial slow-multiplying state bacterial number; kG, growth rate of the
fast multiplying state bacteria; kGLog, growth rate of the fast-multiplying
state bacteria in experiments with rifampicin log phase cultures; F0 initial
fast-multiplying state bacterial number; F0Log ,initial fast-multiplying state
bacterial number in experiments with rifampicin log phase cultures; Bmax,
system carrying capacity; BmaxStationary , system carrying capacity in
experiments with rifampicin stationary phase cultures; FGk, linear
drug-induced inhibition of fast-multiplying state growth; FDEmax ,
maximum achievable drug-induced fast-multiplying state kill rate;
FDEC50 , concentration at 50% of FDEmax ; SDEmax , maximum achievable
drug-induced slow-multiplying state kill rate; SDEC50 , concentration at
50% of SDEmax ; NDk, non-multiplying state kill rate; vF, variability in F0
expressed as coefficient of variation; RSE, relative standard error
reported on the approximate standard deviation scale.
aFixed during drug evaluation.
bkFS = kFSLin .
cgrowth = F · kG · log(Bmax/F + S + N).
Clewe et al.
968
pharmacometric model was as follows:
dF
dt
= F · kG · log BmaxF + S + N
( )
· (1− FGk · CRIF) + kSF · S + kNF · N
− kFS · F − kFN · F − FDEmax · CRIFFDEC50 + CRIF
( )
· F
dS
dt
= kFS · F + kNS · N − kSN · S − kSF · S − SDEmax · CRIFSDEC50 + CRIF
( )
· S
dN
dt
= kSN · S + kFN · F − kNF · N − kNS · N − NDk · N
The residual error from the estimation of the natural growth
data was 40% and the standard errors (RSEs) for all natural
growth-associated parameters were ≤5%. Simultaneous estima-
tion of all parameters resulted in a decrease in OFV (DOFV¼228).
However, the simultaneous estimation resulted in a lower number
of significant digits (1.3) and was not selected as the final model.
As indicated by the pcVPC (Figures 6 and 7) and the individual
fits (Figure S2) the final multistate tuberculosis pharmacometric
model well described the rifampicin effect for awide range of con-
centrations for both log- and stationary-phase cultures. Figure 3
shows the model-predicted change in bacterial numbers over
time for natural growth and after rifampicin exposure in both
the log- and stationary-phase cultures.
Discussion
In this workwe have developed amultistate tuberculosis pharma-
cometric model consisting of three different bacterial states.
Previous work describing the effect of anti-tubercular drugs have
used exponential30 or bi-exponential31,32 models relating to one
or two types of visible bacterial states. A two sub-state model
without the non-growing state resulted in a much poorer fit
(DOFV¼+300) compared with the final multistate tuberculosis
pharmacometric model. In Figure 2, the final model structure of
the multistate tuberculosis pharmacometric model together
with the drug effect model for describing the effect of rifampicin
on log- and stationary-phase cultures is shown. The multistate
tuberculosis pharmacometric model constitutes a semi-
mechanistic pharmacokinetic pharmacodynamics template
model for studying anti-tubercular drug effects.
The model was developed using cfu counts from natural
growth data of M. tuberculosis H37Rv in an in vitro hypoxia system
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Figure 3. Model-predicted typical M. tuberculosis bacterial numbers in the fast-, slow- and non-multiplying states without drug (natural growth) and
after different static rifampicin (RIF) concentrations in log- and stationary-phase cultures.
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together with the decline in cfu counts after different concentra-
tions of rifampicin in log- and stationary-phase cultures. In in vitro
systems, slow- or non-multiplying states of M. tuberculosis are
thought to be induced by hypoxia.14 In the in vitro hypoxic system,
the bacilli initially grow in the top layer of an unagitated culture.
They slowly adapt to microaerophilic and eventually to anaerobic
conditions while sinking and finally settling on the bottom of the
container. At 30–40 days, replication can no longer be detected
and at this point the organisms are in stationary phase.33
In late stationary-phase cultures after 60 days of incubation,
protein synthesis is switched off.34 However, the dormant
stationary-phase bacteria are able to reinitiate protein synthesis
as a response to favourable changes in the environment.34
Furthermore, the ability of M. tuberculosis to remain dormant in
stationary phase whilst retaining the ability to reinitiate multipli-
cation has been shown in vitro,15–17 in vivo19 and in sputum20,21,35
usingmethods involving resuscitation-promoting factors (RPFs). It
remains to be shown whether the hypoxia-driven in vitro system
reflects the same bacterial behaviour that is present in clinical
infections, but the system represents a powerfulmethod of study-
ing antibacterial drug effect not only during exponential growth,
but also during the stationary phase.36,37
In the model presented in this work, culture-positive bacteria
are represented by the fast- and slow-multiplying state and the
culture-negative, but still responsive, bacterial state is repre-
sented by the non-multiplying state (Figure 2). From the cfu
assay it is not possible to directly distinguish between bacteria
in the fast- and slow-multiplying states, as the cfu count is a
sum of the total number of bacteria that are able to multiply on
solid media. It is hence not possible to assign a specific number of
cfu that is associated with either the fast- or the slow-multiplying
state. Instead the model was allowed to estimate the number of
bacteria associated with the fast-multiplying and the slow-
multiplying bacterial states. A similar approach of performing
multiple state predictions based on one observation has previ-
ously been utilized to describe the life cycles of Plasmodium falcip-
arum38 and S. pyogenes.2 As the cfu count reflects only the
bacteria that are able to multiply on solid media, the numbers
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Figure 4. VPC of the final multistate tuberculosis pharmacometric model
using H37Rv M. tuberculosis in vitro without drug (natural growth). Open
circles are observed log10 cfu data, the solid line is the median of the
observed data and the dashed lines are the 5th and 95th percentiles of
the observed data. The top and bottom shaded areas are the 95% CIs
for the 5th and 95th percentiles of simulated data. The middle shaded
area is the 95% CI for the median of the simulated data.
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Figure 5. Correlation between the rate of incorporation of radiolabelled
methionine ([35S]methionine) into proteins by the bacteria and, as a
percentage, the mean of the natural growth model predicted typical fast-
multiplying bacterial number out of the predicted typical fast- plus slow-
multiplying bacterial number.
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Figure 6. pcVPC for log-phase data of the final multistate tuberculosis
pharmacometric model using log- and stationary-phase H37Rv M.
tuberculosis in vitro and different static rifampicin concentrations. Open
circles are prediction-corrected observed log-phase log10 cfu data after
different static rifampicin concentrations, the solid line is the median
of the observed data and the dashed lines are the 5th and 95th
percentiles of the observed data. The top and bottom shaded areas are
the 95% CIs for the 5th and 95th percentiles of simulated data. The
middle shaded area is the 95% CI for the median of the simulated data.
The black solid line in the lower plot is the median of data below the LOQ.
The shaded area in the lower plot is the 95%CI for the simulated LOQ data.
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in the fast- and slow- multiplying states, as a sum, were part of
the model prediction of the data. However, the non-multiplying
state influences the predictions as described in equation 5. This
resulted in a significantly better description of the data as
judged by OFV (DOFV¼2159). Inclusion of non-culturable, non-
multiplying, bacteria in the model structure but outside the predic-
tions of the visible (culture positive) bacteria has previously been
conducted with the same biomarker (cfu) for Escherichia coli.39 It
has also been utilized in describing the life cycle and drug effect on
P. falciparum.40 As the clinical relevance of these non-culturable
bacteria is undoubtedly large, it is naturally of great interest to be
able to quantify drug effect on this type of bacteria.
In the pharmacometric model the growth of the fast-multiply-
ing bacteriawas best captured bya Gompertz growth function. This
growth function involves a cap on growth, i.e. the total carrying
capacity of the system, Bmax. This growth function ismoremechan-
istic than an exponential function that allows the bacterial popula-
tion to grow to an infinite number. However, in a system where
natural growth is observed during a shorter time period, the growth
is equivalent to an exponential function and can replace the
Gompertz function. Previous research has shown that
M. tuberculosis switches off RNA and protein synthesis when enter-
ing stationary phase.34,41,42 This suggests that bacteria in the slow-
multiplying state would have a lower multiplication rate compared
with those in the fast-multiplying state. However, somemultiplica-
tion by bacteria in the slow-multiplying state is still theoretically
possible. The decision not to include growth in the slow-multiplying
state was based on lack of a significant drop in OFV; however, the
authors recognize that growth of the slow-state bacteria is possible
but not supported by the data and the model parameterization
presented.
The rate parameter characterizing movement of bacteria from
the non-multiplying state to the fast-multiplying state, kNF, was
fixed to zero. This transfer is naturally possible in a true mechan-
istic setting and is also seen in vitro when bacteria from
stationary-phase cultures are placed in fresh growth conditions,
exhibiting reinitiation of increased growth. If a culture is reinitiated
from a stationary phase by diluting and placing it in more favour-
able conditions, it is bound to contain non-growing bacteria as it
originated from stationary conditions. These non-growing bac-
teria will then change into fast-growing bacteria. It was, however,
impossiblewith the data used in this analysis to quantify the initial
number of non-multiplying bacteria and hence the transfer from
the non-growing to the fast-growing state. The decision not to
include a natural death rate in the natural growth system was
based on results from a recent study43 that demonstrated that
when M. tuberculosis was grown in vitro, the majority of bacilli
entered a viable but non-culturable stage on solid media, bacilli
were however detectable when using 7H9 liquid medium.
However, a subpopulation of persistent bacilli was only resusci-
tated using RPFs, proteins secreted by M. tuberculosis.44 These
RPF-dependent persisters were also present in sputum.21 It was
clearly demonstrated that the decline in cfu counts after
60 days of incubation was not due to bacterial death. Instead it
was due to the entry of bacilli into a persistent stage, which can
only be ended by RPFs.43 Further, the prediction of the total num-
ber of bacteria in the system was uninfluenced by the number of
dead bacteria, and hence the introduction of a fixed value for the
rate of death will not change the ratio between the other states.
Description of the natural growth of M. tuberculosis H37Rv when
subjected to an in vitro hypoxia system is crucial for obtaining
growth and transfer rates for the bacteria when no drugs
are present. The final multistate tuberculosis pharmacometric
model was very well able to capture, as judged based on the
VPC (Figure 4), the observed changes in cfu over time. The strong
correlation in the external validation (R2¼0.98) speaks highly in
favour of the prediction provided by the model of both the fast-
and the slow-multiplying bacterial numbers over time, as the
incorporation should be drivenmainly by the fast-multiplying bac-
teria,34 which are predicted by themodel to make up themajority
of bacteria in log-phase cultures (Figure 3).
To describe the effect of rifampicin exposure, a compartment
accounting for rifampicin pharmacokinetics was linked to the
multistate tuberculosis pharmacometric model. However, a static
concentration of rifampicin, i.e. no change in concentration over
time, was assumed since therewas no information about degrad-
ation of rifampicin in the systems. Furthermore, no change in
mediawasmade over time that could havemimicked in vivo elim-
ination. Degradation of rifampicin has been shown to occur
in vitro, but the conclusions with regard to loss of activity are
not clear as it is possible that active degradation products
exist.45 Evaluation of the use of a fixed rifampicin degradation
rate with a half-life of 8 days45 with the final log-phase,
stationary-phase or combined model indicated that this might
not be the case as this led to increased OFVs and no improvement
in pcVPCs. In the case of existing degradation, the assumption of a
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Figure 7. pcVPC for stationary-phase data of the final multistate
tuberculosis pharmacometric model using log- and stationary-
phase H37Rv M. tuberculosis in vitro and different static rifampicin
concentrations. Open circles are prediction-corrected observed stationary-
phase log10 cfu data after different static rifampicin concentrations, the
solid line is the median of the observed data and the dashed lines are the
5th and 95th percentiles of the observed data. The top and bottom
shaded areas are the 95% CIs for the 5th and 95th percentiles of
simulated data. The middle shaded area is the 95% CI for the median of
the simulated data. The black solid line in the lower plot is the median of
data below the LOQ. The shaded area in the lower plot is the 95% CI for
the simulated LOQ data.
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static concentration could, of course, lead to a skewed exposure–
response relationship and consequently it is highly advisable to
quantify concentrations over time or in cases where appropriate,
biological activity over time.
The evaluation of differences between the natural growth data
and the log- and stationary-phase natural growth control data in
parameter estimates due to experiment-specific properties
revealed that there were significant differences in the growth
(kG) and initial number of fast-multiplying bacteria (F0) between
the experimental settings of the log and natural growth systems.
A significant difference between the stationary phase and natural
growth was similarly found inmaximum system carrying capacity
(Bmax). Differences in these parameters between the three experi-
ments are visible when plotting the data from all three datasets
used for model development together (Figure 1). There is a clear
difference between the natural growth data and the log-phase
natural growth control data at day 4. Similarly, there is a differ-
ence between the natural growth data and the stationary-phase
natural growth control data at day 100. These differences in
parameter estimates are thought to reflect differences relating
to e.g. the start inoculum and other differences in how the experi-
ments were carried out or, to some extent, differences in experi-
mental conditions. The improvement in describing the log- and
stationary-phase natural growth controls when using separate
kG and F0 for the log-phase data and Bmax for the stationary
phase data compared with using the estimates from natural
growth is shown in Figure S1.
In the final model, using the log- and stationary-phase rifam-
picin treatment data, the rifampicin effect was included as inhib-
ition of the growth function of the fast-multiplying state and as
a kill rate of the fast-, slow- and non-multiplying states.
Differentiation between the drug effect as inhibition of growth
or as a kill rate of the fast-multiplying bacterial state was possible,
possibly due to the inclusion of the maximum and the present
bacterial number in the fast-multiplying state growth function.
It is important to realize that the effect parameterization of
any drug will be heavily dependent on the data, i.e. whether the
bacterial culture is in log or stationary phase. A drug effect that
is studied with bacteria from a log-phase culture will naturally
not have the same ratio between the different growth states
as when comparison is made with a stationary-phase growth
culture. The multistate tuberculosis pharmacometric model
was developed on natural growth, emanating from a hypoxia-
driven in vitro system studied over 200 days, thus capturing
both the log and the stationary phase. As shown, the multistate
tuberculosis pharmacometric model can be used for quantifying
the drug effect on cultures in either log or stationary phase by tak-
ing into account the duration of pre-growth of the bacteria before
subjecting them to the drug effect and evaluating differences in
experiment-specific settings.
All observed data from the natural growth experiments were
above the LOQ. Rifampicin drug effect data below the LOQ
(cfu¼10, 25% for the log-phase and 10% for the stationary-phase
data) were handled by using the M3 method in NONMEM.28 The
final model handles the LOQ data in an adequateway, as indicated
by the pcVPC lower limit of quantification (LLOQ) plots (Figures 6
and 7); a slight under-prediction is present in the log-phase LLOQ
plot (Figure 6) from 24 days and in the stationary-phase LLOQ
plot (Figure 7) at 110 days. This method allows incorporation of
the observations that are under the LOQ by treating them as
categorical data. Non-inclusion of LOQ data has been shown to
introduce substantial bias in parameter estimates46,47 and substi-
tution of LOQ/2 data for LOQ has been reported as inferior to using
the M3 method.48
In summary, the multistate tuberculosis pharmacometric
model provides predictions over time for a fast-, slow-, non-
multiplying bacterial state with and without drug effect. The
model constitutes the groundwork for the possibility of a model-
based drug development approach for novel anti-tuberculosis
compounds, and the application of the model using in vivo data
(animal and clinical) should thus be investigated.
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